Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
4 hedge funds and large institutions have $603K invested in Proshares UltraPro NASDAQ Biotechnology in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
2,206% more call options, than puts
Call options by funds: $784K | Put options by funds: $34K
1.73% more ownership
Funds ownership: 0% → 1.73% (+1.7%)
43% less funds holding
Funds holding: 7 → 4 (-3)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
72% less capital invested
Capital invested by funds: $2.14M → $603K (-$1.54M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Cutler Group
San Francisco,
California
|
+$26.9K |
| 2 |
Morgan Stanley
New York
|
+$23.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$569K |
| 2 |
VF
Virtu Financial
New York
|
-$429K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$116K |
| 4 |
Jane Street
New York
|
-$112K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$76K |
UBIO Hedge Fund Activity: Q4 2016 in Review
4 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q4 2016, worth a combined $603K — down 72% from $2.14M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of UBIO and 1 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Cutler Group, opening a new position worth an estimated $26.9K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $569K sold.
- 4 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q4 2016, down from 7 in Q3 2016.
- Funds reported $603K of Proshares UltraPro NASDAQ Biotechnology stock for Q4 2016, down 72% quarter-over-quarter.
- 1 fund opened new Proshares UltraPro NASDAQ Biotechnology positions in Q4 2016 and 4 closed out, a net change of -3 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q4 2016 was Cutler Group, an estimated $26.9K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q4 2016 was Susquehanna International Group, an estimated $569K sold.
Based on aggregated 13F filings for Q4 2016.